MBX Biosciences, Inc. (MBX)
Nasdaq · Pharmaceutical Preparations · Inc. DE
What they're doing
Between 2026-06-21 and 2026-09-19, public records show 1 signal for MBX Biosciences, Inc.. Most notable: 2026-07-13: Filed 8-K disclosing director or officer change. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-09-19 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Large insider saleAzoulay Salomon (officer) sold $2.1M of stock
- Large insider saleAzoulay Salomon (officer) sold $2.1M of stock
- Insider purchaseHawryluk P. Kent (director) bought $526k of stock
- Material 8-K filingFiled 8-K disclosing material agreement, director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Insider purchaseHawryluk P. Kent (director) bought $273k of stock
- Insider purchaseHoerter Steven L. (director) bought $265k of stock
- Insider purchaseFHMLS X, L.P. (ten_percent_owner) bought $12.0M of stock
- Material 8-K filingFiled 8-K disclosing material agreement
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-08-04 | Azoulay Salomon | officer | S | 370 | 65.77 | $24,335 |
| 2026-08-03 | Smither John W | officer | A | 28,000 | 0 | $0 |
| 2026-08-03 | Hoerter Steven L. | director | A | 71,000 | 0 | $0 |
| 2026-05-08 | Azoulay Salomon | officer | S | 55,000 | 38.38 | $2,110,900 |
| 2026-05-08 | Azoulay Salomon | officer | M | 15,003 | 16 | $240,048 |
| 2026-05-08 | Azoulay Salomon | officer | S | 15,003 | 38.3 | $574,615 |
| 2026-05-08 | Azoulay Salomon | officer | M | 55,000 | 10.46 | $575,300 |
| 2026-05-08 | Azoulay Salomon | officer | M | 55,000 | 10.46 | $575,300 |
| 2026-05-08 | Azoulay Salomon | officer | S | 55,000 | 38.38 | $2,110,900 |
| 2026-05-08 | Azoulay Salomon | officer | M | 15,003 | 16 | $240,048 |
| 2026-05-08 | Azoulay Salomon | officer | S | 15,003 | 38.3 | $574,615 |
| 2026-05-06 | Azoulay Salomon | officer | S | 231 | 29.54 | $6,824 |
| 2026-05-06 | Hawryluk P. Kent | director | S | 607 | 29.54 | $17,931 |
| 2026-05-06 | Azoulay Salomon | officer | S | 231 | 29.54 | $6,824 |
| 2026-05-06 | Hawryluk P. Kent | director | S | 607 | 29.54 | $17,931 |
| 2026-05-01 | Hoerter Steven L. | director | A | 11,938 | 0 | $0 |
| 2026-05-01 | Hoerter Steven L. | director | A | 11,938 | 0 | $0 |
| 2026-03-13 | Hawryluk P. Kent | director | P | 18,500 | 28.41 | $525,585 |
| 2026-03-13 | Hawryluk P. Kent | director | P | 18,500 | 28.41 | $525,663 |
| 2026-02-26 | Hawryluk P. Kent | director | M | 28,768 | 16 | $460,288 |
| 2026-02-26 | Hawryluk P. Kent | director | M | 28,768 | 16 | $460,288 |
| 2026-02-02 | Azoulay Salomon | officer | A | 15,000 | 0 | $0 |
| 2026-02-02 | Bartram Richard | officer | A | 15,000 | 0 | $0 |
| 2026-02-02 | Hawryluk P. Kent | director | A | 35,250 | 0 | $0 |
| 2026-02-02 | Azoulay Salomon | officer | A | 15,000 | 0 | $0 |
| 2026-02-02 | Bartram Richard | officer | A | 15,000 | 0 | $0 |
| 2026-02-02 | Hawryluk P. Kent | director | A | 35,250 | 0 | $0 |
| 2025-10-24 | Hawryluk P. Kent | director | M | 182,859 | 3.25 | $594,292 |
| 2025-10-24 | Hawryluk P. Kent | director | M | 182,859 | 3.25 | $594,292 |
| 2025-10-20 | Hawryluk P. Kent | director | P | 20,000 | 13.64 | $272,800 |
| 2025-10-20 | Hawryluk P. Kent | director | P | 20,000 | 13.64 | $272,790 |
| 2025-10-17 | Hoerter Steven L. | director | P | 20,000 | 13.25 | $265,000 |
| 2025-10-17 | Hoerter Steven L. | director | P | 20,000 | 13.25 | $264,984 |
| 2025-09-26 | FHMLS X, L.P. | ten percent owner | P | 666,666 | 18 | $11,999,988 |
| 2025-09-26 | Heron Patrick J; FHMLS X, L.P.; FHMLS X, L.L.C.; Topper James N; Frazier Life Sciences X, L.P. | director | P | 666,666 | 18 | $11,999,988 |
| 2025-04-08 | Pescovitz Ora H. | director | P | 7,693 | 5.89 | $45,312 |
| 2025-04-08 | Pescovitz Ora H. | director | P | 7,693 | 5.89 | $45,312 |
| 2025-02-18 | GORDON CARL L | director | P | 49,070 | 10.84 | $531,919 |
| 2025-02-18 | GORDON CARL L | director | P | 94,100 | 10.84 | $1,020,044 |
| 2025-02-18 | OrbiMed Genesis GP LLC | director | P | 94,100 | 10.84 | $1,020,044 |
| 2025-02-18 | OrbiMed Genesis GP LLC | director | P | 49,070 | 10.84 | $531,919 |
| 2025-02-18 | GORDON CARL L | director | P | 49,070 | 10.84 | $531,919 |
| 2025-02-18 | GORDON CARL L | director | P | 94,100 | 10.84 | $1,020,044 |
| 2025-02-18 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | director | P | 49,070 | 10.84 | $531,919 |
| 2025-02-18 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | director | P | 94,100 | 10.84 | $1,020,044 |
| 2025-02-14 | GORDON CARL L | director | P | 29,540 | 9.85 | $290,969 |
| 2025-02-14 | GORDON CARL L | director | P | 17,962 | 9.9 | $177,824 |
| 2025-02-14 | OrbiMed Genesis GP LLC | director | P | 17,962 | 9.9 | $177,824 |
| 2025-02-14 | OrbiMed Genesis GP LLC | director | P | 29,540 | 9.85 | $290,969 |
| 2025-02-14 | GORDON CARL L | director | P | 17,962 | 9.9 | $177,824 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.
Recent filings
- 2026-08-27 8-K
- 2026-08-17 144
- 2026-08-14 SCHEDULE 13G/A
- 2026-08-10 SCHEDULE 13D/A
- 2026-08-10 SCHEDULE 13D/A
- 2026-08-06 10-Q
- 2026-08-06 8-K
- 2026-08-05 4
- 2026-08-04 144
- 2026-08-04 144
- 2026-08-04 4
- 2026-08-04 4
- 2026-07-13 8-K
- 2026-07-08 SCHEDULE 13G/A
- 2026-07-08 SCHEDULE 13G/A
- 2026-06-24 SCHEDULE 13G
- 2026-06-12 8-K
- 2026-06-10 144
- 2026-06-09 144
- 2026-06-05 4